Image

The Long-term Benefit of Hydrogel Spacer in Reducing Rectal Radiation Dose in Cervical Cancer Radiation Therapy.

Recruiting
18 - 75 years of age
Female
Phase N/A

Powered by AI

Overview

This study is an exploratory study based on the previous study " A prospective, multicenter, randomized, parallel arm-controlled, superiority clinical study to evaluate the role of hydrogel spacer in reducing rectal radiation dose in cervical cancer radiation therapy", in which additional follow up study on the subjects of the previous study were conducted. Subjects (6 subjects in Phase I; 100 subjects in Phase II, 50 in the test group and 50 in the control group) who completed the pre-study will be enrolled in this study if they are willing to participate in the long-term follow-up by signing the informed consent form.

Description

The purpose of this study is to evaluate the long-term benefit of hydrogel spacer when hydrogel is injected between the rectum and cervix in women undergoing radiation therapy.

Eligibility

Inclusion Criteria:

  • Karnofsky score ≥ 70. Subjects aged ≥ 18 years and ≤ 75 years. Subjects must be able to cooperate in completing the entire study. The subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate MRI.
        No contraindications to CT scanning. Subjects must be able to understand the purpose of the
        trial, voluntarily participate and sign an informed consent form
        Exclusion Criteria:
          -  Subjects whose target tumors have been previously treated (chemotherapy,
             immunotherapy, surgical treatment, etc.) Subjects with other primary malignancies
             Subjects with contraindications to radiotherapy, as determined by the investigators
             Subjects with injection site infections. Subjects who are allergic to the ingredients
             of the device. Subjects whose tumors invade the injection site and affect the
             injection process and injection safety, as determined by the investigators Persons
             with severe mental illness, cognitive impairment and thinking disorders.
        Participants in other drug clinical trials or medical device clinical trials 1 month prior
        to screening Pregnant or lactating women or those who plan to get pregnant within the last
        six months Subjects who cannot be followed up as prescribed by the doctor Other conditions
        that, in the judgment of the investigator, make the subject unsuitable for enrollmen

Study details

Uterine Cervical Neoplasms

NCT05902390

Peking Union Medical College Hospital

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.